AbbVie News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

02.02.24	AbbVie Q4 Profit Decreases, but beats estimates (RTTNews)
09.01.24	AbbVie Announces Launch Of PRODUODOPA In The EU - Quick Facts (RTTNews)
08.01.24	AbbVie Phase 2 Trial Of Lutikizumab Provides Higher Response Rate In Inflammatory Skin Disease (RTTNews)
04.01.24	AbbVie Collaborates With Umoja Biopharma To Develop Novel In-Situ CAR-T Cell Therapies (RTTNews)
02.01.24	AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09.12.23	New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (PR Newswire)
07.12.23	AbbVie To Acquire Cerevel Therapeutics In $8.7 Bln Deal (RTTNews)
06.12.23	AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline (PR Newswire)
05.12.23	AbbVie To Collaborate With BigHat To Discover Next-Gen Therapeutic Antibodies (RTTNews)
05.12.23	AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies (PR Newswire)
30.11.23	AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln (RTTNews)
30.11.23	AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio (PR Newswire)
29.11.23	AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin (RTTNews)
29.11.23	AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC) (PR Newswire)
27.11.23	AbbVie, Genmab Issue Positive FDA, EMA Updates For Epcoritamab To Treat R/R Follicular Lymphoma (RTTNews)
27.11.23	AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma (PR Newswire)
20.11.23	Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever (PR Newswire)
16.11.23	AbbVie Says Ubrelvy Reduced Development Of Headache If Given At Prodrome Phase Of Migraine Attack (RTTNews)
16.11.23	Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine (PR Newswire)
08.11.23	Natrelle® Unveils New "For Every BODY" Campaign (PR Newswire)
02.11.23	Roundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS) (PR Newswire)
01.11.23	BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before (PR Newswire)
27.10.23	AbbVie Raises 2023 Adj. EPS Guidance; Announces 2024 Dividend Increase (RTTNews)
27.10.23	AbbVie Q3 Profit Decreases, but beats estimates (RTTNews)
24.10.23	Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines (RTTNews)
24.10.23	Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines (PR Newswire)
19.10.23	Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project (PR Newswire)
18.10.23	Takeda Settles Tax Dispute With Irish Revenue Commissioners Over Break Fee Received By Shire (RTTNews)
17.10.23	AbbVie's DLBCL Drug EPKINLY, Crohn's Disease Drug RINVOQ Get Health Canada Approval (RTTNews)
16.10.23	AbbVie : Phase 3 Study Of Skyrizi In Crohn's Disease Meets All Primary And Secondary Endpoints (RTTNews)
15.10.23	AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints (PR Newswire)
12.10.23	AbbVie: Upadacitinib Phase 2b Study In Non-segmental Vitiligo Meets Primary Goal (RTTNews)
12.10.23	AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3 (PR Newswire)
11.10.23	AbbVie: Three Ongoing Phase 3 Studies Show Long-term Efficacy Of RINVOQ (RTTNews)
11.10.23	AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis (PR Newswire)
10.10.23	AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023 (PR Newswire)
05.10.23	AbbVie Exercises Exclusive Right, Completes Acquisition Of Mitokinin (RTTNews)
05.10.23	AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline (PR Newswire)
04.10.23	Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy (PR Newswire)
04.10.23	AbbVie to Host Third-Quarter 2023 Earnings Conference Call (PR Newswire)
03.10.23	Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field (PR Newswire)
29.09.23	AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint (RTTNews)
29.09.23	AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma (PR Newswire)
25.09.23	AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R Diffuse Large B-cell Lymphoma (RTTNews)
25.09.23	AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma (PR Newswire)
18.09.23	Allergan Aesthetics: Second Phase 3 Study With OnabotulinumtoxinA Meets Endpoints (RTTNews)
18.09.23	Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence (PR Newswire)
13.09.23	AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students" (PR Newswire)
12.09.23	AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab (RTTNews)
12.09.23	AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester